go-v.orgdoi

Beta-Blocker Heart Attack Trial (BHAT)

BioLINCC (a data-sharing platform funded by the National Institutes of Health) · Vivli · 2018

  • DOI 10.25934/00000012
  • Publisher Vivli
  • Type dataset
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Vivli · Vivli · dataset · 2018

Abstract

To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period. Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event. One-half of the patients were randomly assigned to a beta-blocking drug (propranolol) and one-half to a placebo.

The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction.

Open the resolved locator · 10.25934/00000012

Metadata licence: OpenAlex metadata (CC0)